Rainer Kimmig - Gynecology

Author Information

Rainer Kimmig is affiliated with the Department of Gynecology and Obstetrics at the University of Duisburg-Essen, located at Hufelandstr. 55, 45147 Essen, Germany. His extensive research spans various aspects of gynecology and oncology, focusing on topics such as breast and ovarian cancer, genomic instability, and biomarkers in oncology.

Research Contributions

Rainer Kimmig has made significant contributions to the field of gynecology and oncology through his extensive research. His work in 2022 alone includes studies on predicting survival after breast cancer brain metastases surgery, the role of tumor microenvironment in ovarian cancer, and the combinatorial power of cfDNA, CTCs, and EVs in oncology. Additionally, his research addresses preeclampsia detection, chemoresistance in ovarian cancer, and biomarkers for early triple-negative breast cancer. His work is instrumental in advancing the understanding of cancer biology and improving patient outcomes.

Aliases

The author is also known by the aliases R Kimmig and R. Kimmig. However, the most appropriate and full name is Rainer Kimmig.

Publication and Citation Metrics

Citation Count	13,840
h-index	57
Paper Count	544

Publications:

Prediction of Short and Long Survival after Surgery for Breast Cancer Brain Metastases

DOI: 10.3390/cancers14061437

Year: 2022

Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial

DOI: 10.3390/cancers14051189

Year: 2022

Combinatorial Power of cfDNA, CTCs and EVs in Oncology

DOI: 10.3390/diagnostics12040870

Year: 2022

Abstract P2-02-04: In early breast cancer, the ratios of neutrophils, monocyctes and platelets to lymphocytes significantly correlate with the presence of subsets of circulating tumor cells in blood and disseminated tumor cells in the bone marrow

DOI: 10.1158/1538-7445.sabcs21-p2-02-04

Year: 2022

Soluble endoglin versus sFlt-1/PlGF ratio: detection of preeclampsia, HELLP syndrome, and FGR in a high-risk cohort.

DOI: 10.1080/10641955.2022.2066119

Year: 2022

CAF-Associated Paracrine Signaling Worsens Outcome and Potentially Contributes to Chemoresistance in Epithelial Ovarian Cancer

DOI: 10.3389/fonc.2022.798680

Year: 2022

Soluble PD‐L1 and B7‐H4 serum levels during the course of physiological pregnancy

DOI: 10.1111/aji.13519

Year: 2022

Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse

DOI: 10.1007/s00432-022-03980-9

Year: 2022

Abstract P5-13-33: Longitudinal transcriptional profiling of CTCs in metastatic breast cancer patients receiving the CDK4/6 inhibitor Palbociclib to predict therapy response

DOI: 10.1158/1538-7445.sabcs21-p5-13-33

Year: 2022

Left Ventricular Diastolic Function Following Anthracycline-Based Chemotherapy in Patients with Breast Cancer without Previous Cardiac Disease—A Meta-Analysis

DOI: 10.3390/jcm10173890

Year: 2021

What are the Alternatives to Hysteroscopic Myomectomy?

How to Foster Open Communication?

What Causes Abnormal Clear and Watery Discharge?

What are the Benefits of a BPP?

What are the Challenges in Achieving Responsiveness?

What are the Symptoms of Heartburn in Pregnant Women?

How Does Insulin Resistance Affect Menstrual Cycles?

How is a Foley Catheter Inserted?

What Are Antibiotics?

Why Are Mortality Rates Important?

Partnered Content Networks

Relevant Topics